DexCom, Inc. (DXCM)

Nasdaq · San Diego, California, USA · Founded 1999 · CEO Jake Leach

Valuation summary

$34.11 fair value versus $80.19 in the market, a difference of -57.5%. Rated Sell.

Fair value per share$34.11
Current share price$80.19
Upside / downside-57.5%
Bear case$21.74
Bull case$51.87
Discount rate (WACC)10.4%
Terminal growth3.00%
Market capitalisation$30B
EV / Sales6.1x

About DexCom, Inc.

Founded in 1999. Jake Leach is president and chief executive. DexCom makes continuous glucose monitors — small sensors worn on the body that track blood sugar in real time and send it to a phone, replacing finger-prick testing. The market is expanding well beyond insulin-dependent diabetics into type 2 patients and general metabolic health monitoring.

Investment case

  • Continuous glucose monitoring is still substantially under-penetrated even among insulin users.
  • Expansion into type 2 diabetes multiplies the addressable population.
  • The consumables model produces highly recurring revenue per patient.

Key risks

  • Abbott's Libre competes directly and is priced more aggressively.
  • Reimbursement decisions by insurers determine how fast the market can expand.
  • A US sales force reorganisation caused a growth stumble that damaged credibility.

Recent developments

Revenue by segment

US Sensor & Hardware70%
International30%

Five-year forecast

RevenueFree cash flow
Year 1$5.6B$0.6B
Year 2$6.3B$0.7B
Year 3$7.0B$0.8B
Year 4$7.7B$0.9B
Year 5$8.4B$1.0B

What the street says

The category growth is not in doubt; DexCom's share of it against Abbott is.

Comparable companies: RMD · IDXX · GEHC · MDLN · BSX · IQV · A · CAH

Open the interactive model, price chart and sensitivity grid →